Cannabinoids Clinical Trials Collective Events 
Puff Puff Post
MARCH 10, 2020
InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.
Cannabis Law Report
DECEMBER 14, 2021
(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study. In addition, 66.7%
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Puff Puff Post
MARCH 10, 2020
InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.
Veriheal
JUNE 30, 2023
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.
Cannabis Law Report
FEBRUARY 2, 2022
– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).
Cannabis Law Report
AUGUST 10, 2021
This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. These statements relate to future events or future performance. from 2020 to 2030 and generate revenue of $151.7 billion in 2030.
Cannabis Law Report
DECEMBER 7, 2021
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, 0.59, 95% CI [0.36–0.97]),
Expert insights. Personalized for you.
84 
Let's personalize your content